Wearable Devices Expands to Next-Gen Neural Interaction for Everyday Life After Securing Patent in the United States
YOKNEAM ILLIT, ISRAEL, March 17, 2025 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (the 'Company' or 'Wearable Devices') (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence ('AI')-powered touchless sensing wearables, announced that it has received a notice of allowance for its patent application entitled 'Gesture and Voice-Controlled Interface Device' by the United States Patent and Trademark Office.
Certain claims of the patent protect the Company's revolutionary gesture-controlled interface ability to be used as wearable scale measuring real-world physical properties from the wrist. The patent covers, inter alia, the ability to estimate the weight of an object, the torque that the user applies fastening rotating objects such as screws and faucets, and measuring the force applied by a user when fastening a connector of an electrical cable harness, along with other innovations in the fields of voice commands, user experience, extended reality ('XR') embodiment and brain computer interface.
The innovation covered by the patent may be beneficial in multiple real-world applications, with three dominant use cases: enhancing embodiment for individuals with severe disabilities, increasing productivity in logistics and industrial environments, and improving immersion in virtual environments.
The patent is part of the Company's intellectual property ('IP') strategy to broaden the protection of its core IP globally using patent families that cover multiple future applications of wearable bio-potential sensors and allows the Company to adapt its patent portfolio in real time to future changes in global markets.
'The newly allowed patent demonstrates the power of neural interfaces in enhancing everyday tasks - whether it's weighing groceries, measuring the torque applied when closing a faucet, or ensuring connectors are properly fastened. Now that the patent is secured, we are diligently integrating these advanced features into our products to enrich our customers' lives,' stated Mr. Guy Wagner, co-founder, President and Chief Science Officer of Wearable Devices Ltd.
About Wearable Devices Ltd.
Wearable Devices Ltd. is a pioneering growth company revolutionizing human-computer interaction through its AI-powered neural input technology for both consumer and business markets. Leveraging proprietary sensors, software, and advanced AI algorithms, the Company's innovative products, including the Mudra Band for iOS and Mudra Link for Android, enable seamless, touch-free interaction by transforming subtle finger and wrist movements into intuitive controls. These groundbreaking solutions enhance gaming, and the rapidly expanding augmented reality (AR), virtual reality (VR) and XR landscapes. The Company offers a dual-channel business model: direct-to-consumer sales and enterprise licensing. Its flagship Mudra Band integrates functional and stylish design with cutting-edge AI to empower consumers, while its enterprise solutions provide businesses with the tools to deliver immersive and interactive experiences. By setting the input standard for the XR market, Wearable Devices is redefining user experiences and driving innovation in one of the fastest-growing tech sectors. Wearable Devices' ordinary shares and warrants trade on the Nasdaq under the symbols 'WLDS' and 'WLDSW,' respectively.
Forward-Looking Statement Disclaimer
This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the 'safe harbor' created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'should,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'estimate,' 'anticipate' or other comparable terms. For example, we are using forward-looking statements when we discuss our technology and its potential benefits and our IP strategy. All statements other than statements of historical facts included in this press release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the trading of our ordinary shares or warrants and the development of a liquid trading market; our ability to successfully market our products and services; the acceptance of our products and services by customers; our continued ability to pay operating costs and ability to meet demand for our products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; our ability to comply with applicable regulations; and the other risks and uncertainties described in our annual report on Form 20-F for the year ended December 31, 2023, filed on March 15, 2024 and our other filings with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Skift
23 minutes ago
- Skift
Two Large San Francisco Hotels Could Be Sold Soon
The DJIA jumped 484 points, the Nasdaq was up 297, the S&P 500 rose 72 points, and the 10-year treasury yield was up .02 to 4.29%. Lodging stocks had a really good day, with the REITs taking the lead. SVC was up 7%, INN and XHR were both up 5% and PEB, SHO, WH, H, and VAC were each up more than 4%. Aimbridge Hospitality announced the launch of a dedicated all-inclusive division designed to help owners and brands tap into the rising demand for experience-led all-inclusive hotels and resorts. The new division, to be based in Miami, united core disciplines including operations, commercial strategy, and guest experience, within a unified structure and backed by established brand relationships and deep regional expertise. With qualified opportunities already in the pipeline, Aimbridge expects to finalize its first all-inclusive agreements in the coming months and begin operations under the new division by year-end.
Yahoo
30 minutes ago
- Yahoo
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ('Compass') (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount. Compass intends to use the net proceeds from the offering to conduct initial preparations for commercial readiness, to fund research and clinical development of its product candidates, and for general corporate purposes. Jefferies, Piper Sandler and Guggenheim Securities are acting as joint active bookrunning managers for the offering. Raymond James, Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the offering. Ladenburg Thalmann and D. Boral Capital are acting as co-managers for the offering. A shelf registration statement on Form S-3 relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the 'SEC') on August 30, 2024 and declared effective by the SEC on September 6, 2024. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at A final prospectus supplement and accompanying prospectus will be filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@ Piper Sandler & Co. by mail at 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401 or by email at prospectus@ and Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Compass has built a robust pipeline of novel product candidates designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Forward-Looking Statements Various statements in this release concerning the timing and completion of the public offering on the anticipated terms or at all may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of substantial risks and uncertainties, many of which are outside Compass's control, that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include fluctuations in Compass's stock price, changes in market conditions, the final terms of the public offering and satisfaction of customary closing conditions related to the public offering, as well as those risks more fully discussed in the section entitled 'Risk Factors' in the prospectus supplement and registration statement referenced above and in Compass's Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025 with the SEC and subsequent reports with the SEC. There can be no assurance that Compass will be able to complete the public offering on the anticipated terms. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Compass undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Investor Contactir@ ContactAnna Gifford, Chief of Staffmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
Cathie Wood Bets $19 Million More On Jack Dorsey's Block Amid Bitcoin's All-Time High Push, Dumps Shopify Stock
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Monday, Cathie Wood-led Ark Invest made significant trades involving Block Inc. (NYSE:XYZ) and Shopify Inc. (NASDAQ:SHOP). The Block Trade saw Ark Invest making substantial purchases of the shares across multiple ETFs. The Ark Fintech Innovation ETF (BATS:ARKF) fund acquired 39,957 shares, while the ARK Innovation ETF (BATS:ARKK) added 152,980 shares, and the ARK Next Generation Internet ETF (BATS:ARKW) bought 69,526 shares. The total value of these purchases amounted to approximately $19.2 million, calculated based on Block's last closing price of $73.03. Trending: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — This move comes after Block's recent earnings report, which showed quarterly earnings of 62 cents per share, missing the analyst consensus estimate of 68 cents. Despite this, Block's stock has been gaining attention due to the momentum of its Cash App, as highlighted by analysts. Block's impressive performance in the second quarter has caught the eye of investors. The company reported upbeat earnings, which led to a positive reaction in the stock market. Analysts have been buzzing about the Bitcoin (CRYPTO: BTC)-focused company's potential as a standout performer in this earnings season, with its financial results exceeding expectations in some areas. Bitcoin hovered near its July 14 all-time high of $123,321.10 over the past 24 hours, reaching $122,321.10 on Monday. At the time of writing, it traded at $118,999.21 — about 3.3% below its peak, according to Benzinga Pro Shopify Trade involved Ark Invest selling 69,973 shares of Shopify. through the ARKK fund, amounting to a transaction value of approximately $10.3 million, based on Shopify's last closing price of $147.50. Shopify's second-quarter results showed a 31% year-over-year revenue growth to $2.68 billion, surpassing the analyst consensus estimate of $2.55 billion. Despite the positive sales figures, Ark's decision to sell shares could indicate a strategic move to capitalize on Shopify's current market position. Shopify's strong sales and global momentum have been key factors driving its recent stock performance. The stock has shot up 18.2% over the last 5 days. Even so, Ark has been reducing its exposure to Shopify; Ark sold stock worth $18.4 million last week. Other Key Trades: Personalis Inc. — Bought 59,880 shares via ARKG. Compass Pathways PLC — Bought 23,970 shares through ARKG. Guardant Health Inc. — Sold 7,200 shares through ARKK. CRISPR Therapeutics AG — Bought 1,415 shares through ARKK. Read Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo: ChrisStock82 / This article Cathie Wood Bets $19 Million More On Jack Dorsey's Block Amid Bitcoin's All-Time High Push, Dumps Shopify Stock originally appeared on Sign in to access your portfolio
